Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Strategic analysis of the European tissue sealants market

Although the USD 90 million European tissue sealants market is in the growth phase, the rate of growth is projected to be gradual due to sluggish technological advancements, the slow pace of collecting clinical evidence and unclear product demarcations. Moreover, while around 35 per cent of all internal surgical procedures offer the potential for sealants' use, their deployment has been limited to only a few procedures.

19 Jan 2005

Biopharmaceutical market generated revenues of USD 45.0 billion in 2004

New analysis from Frost & Sullivan, Strategic Analysis of the World Plant Molecular Farming Market, reveals that the biopharmaceutical market generated revenues of USD 45.0 billion in 2004. It is likely to reach USD 98.2 billion by 2011.

17 Jan 2005

Alternative therapies and conventional medical therapies should be held to same standards

Stating that health care should strive to be both comprehensive and evidence-based, a new report from the Institute of Medicine of the National Academies calls for conventional medical treatments and complementary and alternative treatments to be held to the same standards for demonstrating clinical effectiveness.

13 Jan 2005

MHRA and FDA to inspect Chiron's Liverpool manufacturing facility

Chiron Corporation announced at a presentation at the 23rd Annual JPMorgan Healthcare Conference that the company anticipates that the UK Medicines and Healthcare products Regulatory Agency (MHRA), accompanied by U.S. Food and Drug Administration (FDA) inspectors as observers, will conduct a series of inspections of Chiron's Liverpool manufacturing facility.

13 Jan 2005

Escalating demand for novel and effective therapeutic approaches underlines growing appeal of peptides

With a 30 per cent revenue share, Europe trails the United States as the second largest regional market for therapeutic peptides. The rising need for new therapeutic approaches combined with the potential of peptides as active pharmaceutical ingredients for effective drug formulation is contributing to rapid market development.

12 Jan 2005

Safety established for Vaxin's first flu vaccine in clinical trial

Vaxin Inc., a privately-held biotechnology company, has demonstrated, in a Phase I human clinical study, that the company's recombinant influenza vaccine provides a potential alternative to traditional flu vaccines.

12 Jan 2005

FDA clearance to test influenza vaccine, Fluviral

ID Biomedical Corporation announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to begin immediate clinical testing of its influenza vaccine, Fluviral, in the United States under an Investigational New Drug application (IND).

7 Jan 2005

First new leukemia treatment approved specifically for children in more than a decade

Ash Stevens was approved to manufacture the bulk drug substance Clofarabine, the active ingredient in Genzyme Corp.'s Clolar (clofarabine) for the treatment of children with refractory or relapsed Acute Lymphoblastic Leukemia (ALL). This is the first new leukemia treatment approved specifically for children in more than a decade.

4 Jan 2005

Why hair turns grey

Few things about growing older are as inevitable and obvious as "going gray," yet scientists have been unable to explain the precise cause of this usually unwelcome transformation.

23 Dec 2004

Genzyme files for European approval of Myozyme for treatment of Pompe disease

Genzyme Corp. announced today that the European Medicines Agency (EMEA) has accepted its marketing authorization application for Myozyme(R) (alglucosidase alfa), an investigational enzyme replacement therapy for Pompe disease.

20 Dec 2004

GlaxoSmithKline acquires full marketing and development rights for BEXXAR worldwide

GlaxoSmithKline announced that it has reached an agreement with Corixa Corporation to acquire worldwide rights and responsibilities related to the manufacturing, development and commercialization of the BEXXAR® therapeutic regimen.

14 Dec 2004

Patent issued for generating genetically evolved mammalian cells through the regulation of mismatch repair

Morphotek announced today the issuance of United States Patent 6,825,038 covering the regulation of mismatch repair (MMR), a powerful process for generating functional diversity in mammalian cells, to yield sibs exhibiting desirable phenotypes for target discovery, drug screening and/or product development.

13 Dec 2004

Chiron flu vaccine banned for a further three months

The Chiron Corporation, a vaccine manufacturer, were told today that the suspension of their licence for manufacturing influenza vaccine at the Speke factory in Liverpool, would continue for a further three months.

8 Dec 2004

HHS purchases 1.2 million doses of GSK's Fluarix flu vaccine

HHS Secretary Tommy G. Thompson has announced that the Food and Drug Administration authorized the use of GlaxoSmithKline influenza vaccine, Fluarix, in the United States under an Investigational New Drug application.

8 Dec 2004

DNA crystal that computes as it grows

In a demonstration that holds promise for future advances in nanotechnology, California Institute of Technology computer scientists have succeeded in building a DNA crystal that computes as it grows. As the computation proceeds, it creates a triangular fractal pattern in the DNA crystal.

7 Dec 2004

Common ingredient in some shampoos (methylisothiazolinone) stunts developing neurons of rats

An antimicrobial agent found in some shampoos and hand creams and widely used in industrial settings inhibits the development of particular neuron structures that are essential for transmitting signals between cells.

6 Dec 2004

Gene decoding revealed at atomic level

A recent finding by a North Carolina State University biochemist advances the fundamental biology of how genetic information, encoded in DNA, is decoded for the production of proteins.

4 Dec 2004

Low level exposure to Benzene causes lower blood cell counts

A new study found that white blood cell counts were lowered in workers exposed to less than 1 ppm of the chemical benzene (part benzene per million parts air).

3 Dec 2004

Potential vaccine for the deadly toxin ricin

A potential vaccine for the deadly toxin ricin, a "Category B" biological agent, will enter the first phase of clinical testing in coming weeks at UT Southwestern Medical Center at Dallas.

30 Nov 2004

Biopharmaceuticals industry, a rapidly growing sector within the pharmaceuticals industry

Global manufacturing of biopharmaceuticals has increased significantly over the last decade due to a number of reasons. Biopharmaceuticals offer several advantages such as highly effective and potent action, fewer side effects and the potential to actually cure diseases rather than merely treat the symptoms.

30 Nov 2004